Incyte Corp (NQ: INCY )

82.21 USD +1.56 (+1.93%)

Official Closing Price Updated: 5:25 PM EDT, Apr 14, 2021 Add to My Watchlist

Price and Volume

Volume	1,040,500
Open	80.65
Bid (Size)	80.57 (1)
Ask (Size)	83.70 (1)
Prev. Close	80.65
Today's Range	80.54 - 83.22
52wk Range	75.52 - 110.36
Shares Outstanding	218,073,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

April 08, 2021

- Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical...

4 Top Biotech Penny Stocks to Watch in April 2021

April 09, 2021

Performance

YTD	-4.90%	-4.90%
1 Month	+1.93%	+1.93%
3 Month	-11.35%	-11.35%
6 Month	-11.93%	-11.93%
1 Year	-9.94%	-9.94%

More News

Incyte to Report First Quarter Financial Results

April 13, 2021

Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

April 06, 2021

Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2

March 29, 2021

Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene,

March 23, 2021

Tyler Technologies Moves Up In Market Cap Rank, Passing Incyte

April 08, 2021

Drugmakers Are Vying for a Multibillion-Dollar Market

Today 8:05 EDT

Should AbbVie Be Worried About Rinvoq?

Today 7:01 EDT

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ve

March 18, 2021

A Short Delay Is Still Bad News for AbbVie

April 13, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.